Setup

Burford Capital (BUR) lost its primary catalyst on March 27 when the Second Circuit reversed the $16.1B YPF judgment in a 2-1 decision. The stock dropped 47% to $4.14. The YPF thesis is dead in its original form. The question is whether the market priced out the entire operating company in the process.

What the Filing Says

Single 8-K, single press release (Exhibit 99.1). The Second Circuit majority held Argentina's tender offer commitment in the YPF Bylaws was not enforceable by minority shareholders, and that claims should have been brought in Argentine courts. Judge Cabranes dissented. The majority acknowledged Argentina's "knowing and flagrant violation of the promises it made to foreign investors" — then declined to enforce them.

Three residual paths remain. En banc petition due within 14 days — the Second Circuit grants fewer than 12%. SCOTUS cert available after that. Investment treaty arbitration with King & Spalding already engaged. CEO Bogart: "US litigation was never the only path for potential relief here." Argentina has lost multiple ICSID cases, including a prior Burford-funded matter.

The Q1 report (early May) will carry a mandatory write-down of YPF carrying value. If large enough, equity could fall below the debt incurrence threshold in senior note indentures — no default risk, but new debt capacity constrained. Burford recently raised additional capital; amount undisclosed.

The non-YPF business was confirmed intact. FY2025: new commitments up 39% YoY, concluded portfolio IRR 26%, ROIC 83%, capital provision assets up 7% to $5.6B fair value. The headline miss (-24% revenue, -57% net income) was lumpy realizations, not deterioration.

What the Market Thinks

At $4.14 on roughly 220M diluted shares, market cap is approximately $900M. Non-YPF consolidated book value is $3.0B, or $13.60 per share. The market is pricing this portfolio at 30 cents on the dollar. Forward P/E is 3.69 on a business growing commitments 39% year-over-year.

The options term structure splits cleanly. January 2027 put/call ratio is 0.94 — neutral. The market doesn't know where BUR goes in 10 months. January 2028 LEAPS put/call ratio is 0.10 — 10 times more call OI than put. Max pain converges at $8 (Jan 2027) and $10 (Jan 2028). The biggest single position in the entire chain is 8,107 contracts of $20-strike January 2028 calls. Someone is paying for the YPF arbitration tail.

The gap is widest on two variables: non-YPF book credibility and YPF arbitration value. We agree with the market on the tail — full reinstatement is a long shot. The divergence is in the middle: is the operating business worth roughly what it says, and is the arbitration path worth more than zero?

Why the Gap Exists

Forced-seller liquidation. 38 million shares traded on a 3-month average of 1.85 million — 20.6 times normal volume. RSI 13.5. The counterparty selling BUR at $4 is margin calls and momentum stops, not someone with a view on non-YPF portfolio value. Omni Bridgeway, the closest lit-finance comp, was up 4.28% the same day. The market correctly differentiated BUR from its sector. BUR's own shareholder base was the problem.

Accounting opacity. Fair value of litigation assets is management's estimate. Burford missed earnings estimates in 3 of the last 4 quarters. Concluded portfolio data (26% IRR, 83% ROIC) suggests marks are conservative when cases resolve. But unrealized assets dominate the portfolio, and we can't see inside them. Rational investors can justify sitting this out on accounting risk alone.

Covenant uncertainty creates a near-term binary. The Q1 write-down could breach the indenture threshold, and we don't know the threshold or the capital raise size. This is a defined risk window between now and May 6 — five weeks of binary exposure that overlays the fundamental question.

Risks

1. Non-YPF book value is overstated (highest impact). If the $3.0B is 30-50% inflated, the "discount to book" thesis collapses. This is the risk that determines whether BUR at $4 is a gift or a trap. We cannot independently verify the unrealized portfolio from outside the company.

2. Covenant breach constrains the growth engine. If the write-down breaches the indenture threshold and no waiver or capital raise solves it, Burford's ability to deploy into new cases stalls at the moment the pipeline is growing fastest. The undisclosed capital raise partially mitigates — but "undisclosed" means we can't size the mitigation.

3. Arbitration is a decade, not a catalyst. King & Spalding is credible. Argentina is a serial ICSID loser. But 5-10 years of process, uncertain quantum, and sovereign collection difficulty make the present value a fraction of the $16.1B judgment that just disappeared.

4. Further forced selling. If the stock breaches additional margin or fund thresholds, mechanical selling continues. Short interest is modest (4.4%) but shorts aren't covering.

Catalysts

May 6, 2026 — Q1 report. The single most important date. Write-down magnitude, covenant status, and non-YPF book value all revealed. Everything before this is positioning; everything after depends on it.

April-May — Volume normalization. When daily volume drops from 38M back to 2-5M, forced sellers are exhausted and the stock finds a fundamental floor. Two to four weeks.

Q2-Q3 2026 — En banc decision. Likely denied (88%). Small negative for the YPF path, but resolves one gate. Unexpected grant would be significant.

H2 2026 — Arbitration filing. Formal ICSID commencement puts a floor under YPF option value. 80-85% probability it happens by year-end.

What Would Change Our Mind

Q1 report shows non-YPF capital provision assets below $2.5B — that's more than 17% below current marks, and would mean the book values are unreliable rather than conservative. The 70% market discount would be justified.

Insider selling in the next 30 days. If management is dumping at $4, the non-YPF book story is hollow.

Auditor qualification or going concern language in Q1 filing.

Covenant breach with no capital raise solution and no waiver — growth engine impaired for 12-18 months.

Evidence